EUVIMEDEUVIMED entdecken
Crossref

Palopegteriparatide (Yorvipath)

CDA-AMC

Canadian Journal of Health Technologies · 03.11.2026 · 6 (11)

DOI: 10.51731/cjht.2026.1563 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Canadian Journal of Health Technologies, online erschienen am 03.11.2026. Verfasst von CDA-AMC.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec. This review assesses palopegteriparatide (Yorvipath) 168 mcg/0.56 mL, 294 mcg/0.98 mL, and 420 mcg/1.4 mL solution for subcutaneous injection. Indication: For the treatment of chronic hypoparathyroidism in adults.

Zitieren

APA

CDA-AMC (2026). Palopegteriparatide (Yorvipath). Canadian Journal of Health Technologies, 6(11). https://doi.org/10.51731/cjht.2026.1563

Vancouver

CDA-AMC. Palopegteriparatide (Yorvipath). Canadian Journal of Health Technologies. 2026;6(11). doi:10.51731/cjht.2026.1563

BibTeX
@article{CDAAMC2026,
  author = {CDA-AMC},
  title = {Palopegteriparatide (Yorvipath)},
  journal = {Canadian Journal of Health Technologies},
  year = {2026},
  volume = {6},
  number = {11},
  doi = {10.51731/cjht.2026.1563}
}
Kostenlos starten →